J&J loses Hatch-Waxman case to Eon on Sporanox

A district court ruled that a generic version of Johnson & Johnson nail fungus drug Sporanox proposed by Eon does not infringe a company patent, the Janssen Pharmaceutica unit of J&J reported on July 29, 2004.

The decision affects only US sales of the drug, which, in 2004Q2, comprised only $32 million of worldwide sales of $170 million.